A report released today by B. Riley about Nuvectra Corp (NASDAQ:NVTR) ups the target price to $12.00
- Updated: September 15, 2016
Having a price of $6.30, Nuvectra Corp (NASDAQ:NVTR) traded 1.72% lower on the day. The last close is down 13.25% relative to the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same time period. Nuvectra Corp has registered a 50-day average of $6.83 and two hundred day average of $7.26. 21,466 shares of NVTR traded hands, down from ann average volume of 87,564
In a report released on Thursday September 15 2016 B. Riley upped the target price of Nuvectra Corp (NASDAQ:NVTR) from $0 to $12 indicating a possible upsideof 0.90%.
A total of 2 analysts have reported on Nuvectra Corp. Zero rate the stock a strong buy, 0 rate the stock a buy, one firm rate the company a hold, 0 rate the company to underperform, and finally 0 analystsrate the stock as sell with an average target stock price of $13.00
Nuvectra Corp has a one-year low of $4.02 and a one-year high of $11.64 and has a market cap of $0.0.
Brief Synopsis On Nuvectra Corp (NASDAQ:NVTR)
Nuvectra Corporation, formerly QIG Group, LLC, is a neurostimulation company. The Company is focused on the development and commercialization of a neurostimulation technology platform, which is used for the treatment of various disorders through stimulation of tissues associated with the nervous system. The Company’s Algovita spinal cord stimulation (SCS) system is an application of its neurostimulation technology platform, and is used for the treatment of chronic pain of the trunk and limbs. The Company’s technology platform supports other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, the Company, through its subsidiary, designs, and manufactures and markets neural-interface technologies for the neuroscience pre-clinical research market.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.